{"filings":[{"id":913876,"accession_number":"0001493152-26-027688","cik":2010788,"company_name":"EXOZYMES INC.","ticker":"EXOZ","form_type":"8-K","filed_at":"2026-06-08T18:19:49+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"eXoZymes prices $5.33M offering of common stock and warrants at $18/unit","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 592,270 shares and 296,135 warrants as units at $18.00; gross proceeds ~$5.33M.","Warrants exercisable after 1 year at $11.24/share, expire in 5 years; redeemable at $0.01 if stock ≥ $17.98.","Underwriter MDB Capital; over-allotment option for additional 44,420 units (45 days).","Net proceeds to fund NCT development, R&D, and general corporate purposes; close expected June 9, 2026.","Warrant exercise price resets to $0.001 if Company sells shares below $8.99 within 12 months (subject to holding requirement)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":82246222.39999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":97181,"accession_number":"0001493152-26-021589","cik":2010788,"company_name":"EXOZYMES INC.","ticker":"EXOZ","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"eXoZymes files 8-K with investor presentation for proposed public offering","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company disclosed it is pursuing a proposed public offering of securities; no specific terms provided in the filing.","Investor presentation furnished as Exhibit 99.1; content not available in this extract for detailed analysis.","Presentation is being provided to potential underwriters and offering participants for the proposed offering.","eXoZymes is an emerging growth company trading on Nasdaq under ticker EXOZ."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":82246222.39999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":97180,"accession_number":"0001493152-26-016227","cik":2010788,"company_name":"EXOZYMES INC.","ticker":"EXOZ","form_type":"8-K","filed_at":"2026-04-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"eXoZymes shares investor presentation for proposed securities offering (April 10, 2026)","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation provided to potential underwriters and offering participants for a proposed securities offering.","No specific offering terms (size, price, use of proceeds) disclosed in the 8-K or appended exhibit.","Company is an emerging growth company; common stock trades on Nasdaq under ticker EXOZ."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":82246222.39999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111743,"accession_number":"0001493152-26-013733","cik":2010788,"company_name":"EXOZYMES INC.","ticker":"EXOZ","form_type":"8-K","filed_at":"2026-03-31T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"eXoZymes files updated investor presentation for NCTx business; no details provided","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["eXoZymes furnished an updated Investor Presentation dated March 30, 2026 for its NCTx business.","Exhibit 99.1 is attached but its specific content was not included in the filed text.","No financial figures, guidance changes, or material events are disclosed in the filing.","The filing is a routine update; no operational or financial specifics are available."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":82246222.39999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111742,"accession_number":"0001493152-26-005176","cik":2010788,"company_name":"EXOZYMES INC.","ticker":"EXOZ","form_type":"8-K","filed_at":"2026-02-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"eXoZymes reports 535g NCT pilot run at 99% conversion, 90% yield, 99.6% purity","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Achieved ~99% reaction conversion, 90% isolated yield, and 535 g of NCT at 99.6% pharma-grade purity from a 100L pilot run.","Production executed externally by Cayman Chemical, demonstrating protocol transferability and operational robustness.","High-purity NCT is now available for formulation development and partner sample requests.","Company expects 2026 focus on commercial NCT supply chain, expanded volumes, and strategic partnerships."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":82246222.39999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128369,"accession_number":"0001493152-25-027327","cik":2010788,"company_name":"EXOZYMES INC.","ticker":"EXOZ","form_type":"8-K","filed_at":"2025-12-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"eXoZymes achieves 100× scale-up of NCT production with >99% feedstock conversion","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Scaled NCT production 100-fold using proprietary exozyme cell-free platform, achieving >99% conversion from feedstock to product.","Batch executed under partner-operated conditions by Cayman Chemical, demonstrating process robustness and transferability.","CEO Michael Heltzen calls milestone an inflection point for cell-free enzyme-driven biomanufacturing.","Additional technical details and NCT extraction results expected in early 2026 after downstream analysis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":82246222.39999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128368,"accession_number":"0001493152-25-022295","cik":2010788,"company_name":"EXOZYMES INC.","ticker":"EXOZ","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"ExoZymes files updated investor presentation for NCTx business; no specific financial data disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["eXoZymes issued an updated investor presentation dated November 13, 2025, focusing on its NCTx business.","No new financial metrics, guidance, or operational milestones were included in the filing text.","The presentation content was not appended; only the exhibit description was provided.","Investors should review the full presentation for details, which is available as Exhibit 99.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":82246222.39999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128367,"accession_number":"0001493152-25-016831","cik":2010788,"company_name":"EXOZYMES INC.","ticker":"EXOZ","form_type":"8-K","filed_at":"2025-10-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"ExoZymes files updated investor presentation as of September 30, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Investor presentation filed as Exhibit 99.1 to Form 8-K on October 3, 2025","Presentation dated September 30, 2025, updated company materials","Report signed by Vice President of Finance Fouad Nawaz"],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":82246222.39999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":145174,"accession_number":"0001641172-25-021084","cik":2010788,"company_name":"EXOZYMES INC.","ticker":"EXOZ","form_type":"8-K","filed_at":"2025-07-28T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"eXoZymes shareholders elect all six director nominees, approve compensation and 2025 equity plan at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All six director nominees (Marlett, DiGiandomenico, Bowie, Lalonde, Bell, Rayo) elected with at least 4.25M votes for.","Non-binding advisory resolution on executive compensation approved: 4,272,987 for, 1,801 against.","Shareholders voted for a three-year frequency of future advisory votes on executive compensation (4,121,899 for three years).","2025 Performance Equity Plan approved: 4,181,189 for, 92,840 against.","Ratification of RBSM LLP as auditor for FY2025 received 4,779,589 votes for; quorum was 56.98%."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":82246222.39999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":145173,"accession_number":"0001641172-25-018053","cik":2010788,"company_name":"EXOZYMES INC.","ticker":"EXOZ","form_type":"8-K","filed_at":"2025-07-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"eXoZymes files updated Investor Presentation; no material disclosures in filing","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Filing contains only a reference to an updated Investor Presentation as Exhibit 99.1.","No specific financial, operational, or strategic details were provided in the 8-K or exhibits.","Investors cannot derive any material change from this filing alone.","The presentation itself is not included in the provided text for review."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":82246222.39999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163585,"accession_number":"0001641172-25-016681","cik":2010788,"company_name":"EXOZYMES INC.","ticker":"EXOZ","form_type":"8-K","filed_at":"2025-06-26T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"eXoZymes to receive $3M from NSF as key partner in $9.2M cell-free biomanufacturing initiative","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Selected as core industrial partner in Meta-PURE, a $9.2M NSF-funded project under CFIRE program.","eXoZymes awarded approximately $3M share to develop a cell-free ATP-generating module and a santalene production module.","Project led by Georgia Tech; coalition includes academic and industry groups; starts July 1, 2025, for three years.","eXoZymes' technology enables plug-and-play modular cell-free biomanufacturing for multiple market-relevant targets."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":82246222.39999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163584,"accession_number":"0001641172-25-015782","cik":2010788,"company_name":"EXOZYMES INC.","ticker":"EXOZ","form_type":"8-K","filed_at":"2025-06-20T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"eXoZymes increases CEO base salary to $450K, grants options and $250K bonus","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Michael Heltzen base salary raised to $450,000 annualized.","Granted options to purchase 235,817 shares at $12.40 per share, vesting quarterly over 4 years.","One-time bonus of $250,000 approved.","Options vesting starts July 1, 2025; expires June 29, 2032."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":82246222.39999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163583,"accession_number":"0001641172-25-002396","cik":2010788,"company_name":"EXOZYMES INC.","ticker":"EXOZ","form_type":"8-K","filed_at":"2025-04-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"eXoZymes provides Q4/FY2024 operational update; pre-revenue, advancing AI and commercialization","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Completed IPO on Nasdaq on Nov 13, 2024; trades as EXOZ.","Developed proprietary AI process to generate enzyme data, speeding up enzyme development.","Focus on commercialization via spin-outs, joint ventures, and licensing deals.","Remains pre-revenue; no financial results disclosed in the update.","CEO cites milestones toward first commercial applications as key focus."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":82246222.39999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163582,"accession_number":"0001641172-25-002394","cik":2010788,"company_name":"EXOZYMES INC.","ticker":"EXOZ","form_type":"8-K","filed_at":"2025-04-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"eXoZymes appoints Damien Perriman as CCO to lead commercial growth","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Damien Perriman appointed to newly created CCO role, effective April 2, 2025.","Perriman brings 20+ years experience commercializing biotechnologies; previously at Genomatica (Geno) and Gevo.","Focus on commercial opportunities, spin-outs, joint ventures, and licensing deals with future partners.","CEO Michael Heltzen: hire reflects strategic focus on scaling and commercializing biosolutions across multiple sectors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":82246222.39999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":181482,"accession_number":"0001493152-25-007884","cik":2010788,"company_name":"EXOZYMES INC.","ticker":"EXOZ","form_type":"8-K","filed_at":"2025-02-21T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"eXoZymes President and Chairman Mohammad Hayat resigns; Rayo, Marlett appointed","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mohammad Hayat resigned as director, President, and Chairman of eXoZymes Board on February 17, 2025.","Edgardo Rayo appointed as director to fill vacancy; no compensation arrangement currently in place.","Christopher A. Marlett appointed as Chairman of the Board on the same date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":82246222.39999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":181481,"accession_number":"0001493152-25-005961","cik":2010788,"company_name":"EXOZYMES INC.","ticker":"EXOZ","form_type":"8-K","filed_at":"2025-02-11T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Invizyne Technologies renamed eXoZymes Inc. effective Feb 10, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Name changed from Invizyne Technologies Inc. to eXoZymes Inc. via certificate of amendment filed Feb 10, 2025.","Trading symbol remains EXOZ on Nasdaq Capital Market; no ticker change announced.","Principal executive offices in Monrovia, CA, and Nevada incorporation unchanged.","No changes to business operations, management, or financial guidance disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":82246222.39999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":198273,"accession_number":"0001493152-24-046545","cik":2010788,"company_name":"EXOZYMES INC.","ticker":"EXOZ","form_type":"8-K","filed_at":"2024-11-18T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Invizyne completes $15M IPO; shares begin trading on Nasdaq under IZTC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Priced 1,875,000 shares at $8.00; gross proceeds $15M, net proceeds ~$14.3M.","Concurrent private placement issued 93,750 warrants at $0.125, exercisable at $8.00 for 5 years.","Underwriter has 45-day option to purchase up to 281,250 additional shares for over-allotments.","Net proceeds to fund production capacity, business development, repayment of related-party loan, and working capital.","SAFEs from July 2023 converted into 125,001 shares of common stock upon IPO closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":82246222.39999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}